Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

74.59 +1.13 (+1.54%)
Streaming Delayed Price Updated: 1:46 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Proposed Public Offering
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Company to provide update on its emerging pipeline of high-value immunology programs 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.